8-KThe WireStrategic
Results of Operations · Reg FD Disclosure
Filed Apr 29, 2026 · 2mo ago · Accession 0001171843-26-002796
Plain English
Teva Pharmaceutical Industries Ltd. announced its financial results for the quarter ended March 31, 2026, and entered into a definitive agreement to acquire Emalex Biosciences on April 29, 2026.
Filing details
- Ticker
- TEVA
- CIK
- 818686
- Form type
- 8-K
- Filing date
- Apr 29, 2026
- Report date
- Apr 29, 2026
- Document
- f8k_042926.htm
- Size
- 600 KB